Reduction in plasma norepinephrine during fenfluramine treatment

Clin Pharmacol Ther. 1977 Feb;21(2):216-21. doi: 10.1002/cpt1977212216.

Abstract

Plasma norepinephrine levels were reduced to 30% of placebo levels during the administration of fenfluramine, 120 mg/day, for 10 or more days. There was also a significant reduction in plasma dopamine beta-hydroxylase activity during fenfluramine treatment, suggesting that chronic administration may induce antiadrenergic effects which may be useful in the treatment of disorders affected by circulating catecholamines.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Blood Pressure / drug effects
  • Body Weight / drug effects
  • Clinical Trials as Topic
  • Depression / drug therapy
  • Depression, Chemical
  • Dopamine beta-Hydroxylase / blood
  • Female
  • Fenfluramine / administration & dosage
  • Fenfluramine / pharmacology*
  • Fenfluramine / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Norepinephrine / blood*
  • Posture
  • Pulse / drug effects
  • Time Factors

Substances

  • Fenfluramine
  • Dopamine beta-Hydroxylase
  • Norepinephrine